Story updated at 3 p.m. June 3: The first clinical results for new cancer treatments from Amgen injected a little energy into its stock June 3, which has hovered near 52-week lows for two weeks. Shares rose 3.4 percent for the day after the Thousand Oaks company announced Phase 1 data for AMG 510, a…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
